Pfizer is one of the world’s largest research-based pharmaceutical company. It has a long history of operating in Sandwich, Kent. Today, the Pfizer site in Sandwich employs 700 people at Discovery Park. Its Pharmaceutical Sciences facility directly employs 350 people who support the development of the company’s mid-and late-stage portfolio of potential new medicines. A further 350 people are employed in specialist roles, including Worldwide Safety & Regulatory Affairs, Quality Assurance, and Development Operations.
Peakdale Chemistry Services is a leading provider of medicinal chemistry and chemistry services to the pharmaceutical, bio-tech and associated industries. A subsidiary of Peakdale Molecular, they were the first non-Pfizer business to relocate to Discovery Park, Sandwich. Operating from state-of-the-art laboratories, Peakdale offers a full complement of chemistry services from research, synthesis, process development and scale-up projects. Over 85% of Peakdale’s employees are PhD-level scientists.
Mylan is a leading developer and supplier of generic medicines with over 350 products sold to retailers and wholesalers, and throughout the NHS. The company supplies over 60 million packs of medicine every year.
Mylan’s Global Respiratory Group and ‘centre of excellence’ is based at the Discovery Park Enterprise Zone, where it is developing, manufacturing and commercialising generic and branded inhaled products for the treatment of conditions such as asthma and COPD.
The parent company, US-based Mylan Inc. is one of the world’s largest generics and speciality pharmaceutical companies with sales in over 140 countries worldwide.
Genea Biomedx is an IVF technology business, formed in 2013 by Genea, one of the world’s leading fertility treatment experts. Based in Australia, the company has over 26 years experience in infertility R&D and treatment.
Genea Biomedx chose the Discovery Park Enterprise Zone as its Northern Hemisphere base for manufacturing and distribution due to the high standard of the laboratory facilities, and its excellent location for targeting new markets in Europe, the US and Asia.
From its base at the Discovery Park Enterprise Zone, AlgaeCytes is developing and commercialising the next generation of bioactive ingredients for the nutraceutical and pharmaceutical markets. In particular, the company is working on the production of Omega 3 oils and proteins from marine algae by recycling carbon dioxide and water.
Currently up to 90% of the world’s production of Omega 3 oils is produced from oily fish. With rising demand from the pharamaceutical and food production industries clinical trials confirm the health benefits of Omega 3, AlgaeCytes is at the forefront of the development of sustainable production methods.